Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2020 | KarMMa: Idecabtagene vicleucel for R/R MM

Nikhil Munshi • 1 Jun 2020
ASCO 2020
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, updates us on results from the KarMMa study (NCT03361748), investigating idecabtagene vicleucel, a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nikhil Munshi

A novel CAR T-cell therapy targeting the intracellular protein MZB1 for multiple myeloma
2:21
A novel CAR T-cell therapy targeting the intracellular protein MZB1 for multiple myeloma
Nikhil Munshi • 6 Dec 2025
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
1:44
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
Nikhil Munshi • 6 Dec 2025
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
1:32
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
Nikhil Munshi • 19 Oct 2024
Immunotherapies in the future treatment landscape for Waldenström's macroglobulinemia
1:04
Immunotherapies in the future treatment landscape for Waldenström's macroglobulinemia
Nikhil Munshi • 19 Oct 2024

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Nikhil Munshi • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Nikhil Munshi • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Nikhil Munshi • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Nikhil Munshi • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals